Metastatic Bladder Cancer – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033
Metastatic bladder cancer, alternatively known as advanced or stage 4 bladder cancer, involves the dissemination of cancer cells from the primary tumor, enabling them to pass through the lymphatic system or bloodstream to distant regions of the body. The most common sites for the distant metastasis of bladder cancer include the lungs, prostate, uterus, vagina, bones, and liver. Stage 4 bladder cancer comprises two distinct subtypes:
- Stage 4A: In this stage, the cancer has extended beyond the confines of the bladder into adjacent regions, such as the abdominal or pelvic walls. It may have also spread to the lymph nodes.
- Stage 4B: At this advanced stage, the disease has progressed further, invading one or more distant tissues or organs, such as the bones, lungs, liver, or abdominal lining.
The precise mechanism of metastasis remains incompletely understood; it is believed to involve various factors, including genetic alterations and angiogenesis. The pathophysiology of metastatic bladder cancer is intricate and encompasses numerous factors. The pivotal events in this process contain genetic changes enabling cancer cells to proliferate uncontrollably, the secretion of factors stimulating the growth of blood vessels (angiogenesis), and the capability of cancer cells to infiltrate and spread to other body regions. Several factors increase the risk of metastatic bladder cancer - High-grade tumor: Tumors with a high grade are more prone to metastasis, Muscle-invasive tumor- Tumors that have penetrated the muscle layer of the bladder wall are at a higher risk of metastasis, Distant metastases at diagnosis- If a patient presents with distant metastases upon diagnosis, it signifies that the cancer has already disseminated to other body parts, Specific genetic mutations- Certain genetic mutations, such as those in the TP53 gene, are linked to an elevated risk of metastasis, Advanced age- Older adults are more susceptible to developing metastatic bladder cancer. Chemotherapy is a systemic treatment approach commonly involving a combination of cisplatin drugs. Immune checkpoint inhibitors like pembrolizumab, durvalumab, atezolizumab, and avelumab (Bavencio) are used to manage bladder cancer. Enfortumab vedotin (Padcev) is a monoclonal antibody utilized to treat metastatic bladder cancer. For cases of metastatic bladder cancer with mutations in the FGFR2 or FGFR3 gene that are unresponsive to chemotherapy, erdafitinib (Balversa) can be employed. Metastatic bladder cancer can give rise to various complications, contingent on the locations in which the cancer has spread. Complications associated with advanced bladder cancer may encompass erectile dysfunction, anemia, urinary incontinence, urinary tract infections (UTIs), or inflammation.
Thelansis’s “Metastatic Bladder Cancer Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Metastatic Bladder Cancer treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).
KOLs insights of Metastatic Bladder Cancer across 8 MM market from the centre of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs.
Metastatic Bladder Cancer Market Forecast Patient Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario, Summary, and Insights.
Thelansis Competitive Intelligence (CI) practice has been established based on a deep understanding of the pharma/biotech business environment to provide an optimized support system to all levels of the decision-making process. It enables business leaders in forward-thinking and proactive decision-making. Thelansis supports scientific and commercial teams in seamless CI support by creating an AI/ ML-based technology-driven platform that manages the data flow from primary and secondary sources.
Comments
Post a Comment